Kymera raises funds, holds ~$963M; Sanofi backs IRAK4, Gilead pays $40M as R&D burn climbs

Snapshot - Kymera Therapeutics, Inc. (NASDAQ: KYMR)

What's happening inside: Kymera closed a large follow‑on equity raise in June 2025 (initial close $250.8M; underwriters later exercised options bringing total primary proceeds to ~$288.4M) and announced a $40M option/licensing upfront from Gilead (CDK2). Sanofi elected full participation on the IRAK4 program and will advance the next‑generation degrader into the clinic. Management is accelerating STAT6 investment while pausing the TYK2 clinical push to conserve resources. The balance sheet now carries ~ $963.1M of cash + marketable securities, and management says runway extends into the second half of 2028.

Key facts & statistics (as reported June 30, 2025)

* Cash and cash equivalents: $335,816 (thousands)

* Marketable securities (total fair value): $627,258 (thousands)

* Cash + marketable securities: ~$963.1 million (management disclosure)

* Total assets: $1,131,068 (thousands)

* Total liabilities: $159,588 (thousands)

* Stockholders' equity: $971,480 (thousands)

* Shares outstanding (June 30, 2025): 70,557,442

* Pre‑funded warrants outstanding: 15,815,253

* Accounts receivable (billed Gilead): $40,000 (thousands)

* Deferred revenue (current): $40,000 (thousands)

Income statement - select quarterly / YTD numbers

* Collaboration revenue - Q2 2025: $11,476 vs Q2 2024: $25,650 (thousands)

* Collaboration revenue - 6M 2025: $33,576 vs 6M 2024: $35,937 (thousands)

* Research & development - Q2 2025: $78,388 vs Q2 2024: $59,202 (thousands)

* R&D - 6M 2025: $158,643 vs 6M 2024: $108,021 (thousands)

* General & administrative - Q2 2025: $17,645 vs Q2 2024: $17,373 (thousands)

* Operating loss - Q2 2025: $(84,557) vs Q2 2024: $(50,925) (thousands)

* Net loss - Q2 2025: $(76,614) vs Q2 2024: $(42,062) (thousands)

* Net loss per share (basic & diluted) - Q2 2025: $(0.95) vs Q2 2024: $(0.58)

* Weighted average common shares (incl. pre‑funded warrants) used in EPS - Q2 2025: 80,449,405

Cash flow highlights (six months)

* Net cash used in operating activities - 6M 2025: $(139,034) (thousands)

* Net cash provided by investing activities - 6M 2025: $108,636 (thousands)

* Net cash provided by financing activities - 6M 2025: $245,984 (thousands) (driven by June follow‑on)

* Net increase in cash - 6M 2025: $215,586 (thousands)

Positive aspects (income statement & finances)

* Strong liquidity: cash + marketable securities ≈ $963.1M - management cites runway into H2 2028.

* Recent non‑dilutive collaboration inflows and milestone recognition: Sanofi revenue + milestone conversions contributed $33.6M YTD; Gilead upfront $40M booked as contract liability / accounts receivable.

* Access to capital: successful June 2025 follow‑on (initial close net proceeds ~$237.3M) and subsequent underwriter option exercise (~$37.6M) - balance sheet substantially strengthened.

* Interest and other income supporting other income line: Q2 interest & other income $8,051 (thousands).

Negative aspects (income statement & risks)

* Collaboration revenue down Q/Q: Q2 2025 revenue $11.5M vs Q2 2024 $25.7M - greater quarter‑to‑quarter variability tied to milestone timing.

* Rapidly rising R&D spend: R&D up to $78.4M in Q2 2025 (+$19.2M vs prior year Q2); STAT6 program alone was a material driver (STAT6 external spend 6M 2025: $42,798 vs 6M 2024: $15,626 - +$27.2M).

* Heavy operating cash burn: $139.0M used in operations in first half of 2025.

* Widening operating and net losses: 6M net loss $(142,195) vs prior year $(90,619) - EPS worsened to $(1.77) YTD.

* Dilution risk: recent equity raise and 15.8M pre‑funded warrants outstanding (exercise price $0.0001) already included in weighted shares - potential for further share count growth.

* Concentration of revenue sources: meaningful revenue tied to collaboration milestones (Sanofi, Gilead); future revenue visibility is contingent on partners, milestones and successful R&D progress.

Straightforward takeaway - near term

Kymera has substantially strengthened its balance sheet in mid‑2025 and has material cash + securities (~$963M) that, per management, funds operations into late 2028. That gives the company runway to advance STAT6 (clinical), IRAK4 (now Sanofi‑led clinical progress) and IND‑enabling IRF5 work. But investors should watch two critical items: (1) the high and rising R&D burn (STAT6 is a big driver) that keeps cash consumption elevated despite the large raise, and (2) revenue variability because collaboration cash/events (milestones, option exercises) drive near‑term top‑line recognition. The company's story is execution‑and‑catalyst driven: positive clinical news or exercised options could be value inflection points - missed milestones or continued rising burn without new non‑dilutive revenue would increase dilution risk and compress valuation.

Watchlist next 6-12 months: STAT6 clinical readouts and timelines; Sanofi development path for KT‑485; any Gilead option exercise or milestone payments; quarterly cash burn vs guidance; and dilution from future equity or warrant activity.